Aligos Therapeutics (ALGS) Research & Development (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Research & Development came in at $23.4 million in Q1 2026, up 61.03% YoY from $14.5 million in Q1 2025, and up 37.06% on a QoQ basis from $17.0 million in Q4 2025.
Aligos Therapeutics (ALGS) Research & Development (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Research & Development data on file, last reported at $23.4 million in Q1 2026.
- Quarterly Research & Development rose 61.03% year-over-year to $23.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.3 million (up 14.47% YoY) and the FY2025 annual result came in at $69.5 million, down 1.16% from the prior year.
- Research & Development grew to $23.4 million in Q1 2026, from $17.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $31.7 million in Q1 2022 to a low of $14.0 million in Q2 2025.
- A 5-year average of $18.9 million and a median of $17.0 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development plunged 42.75% — and 2026, when it jumped 61.03%.
- Tracing ALGS's Research & Development over 5 years: stood at $19.1 million in 2022, then climbed by 16.53% to $22.3 million in 2023, then declined by 27.97% to $16.0 million in 2024, then grew by 6.28% to $17.0 million in 2025, then jumped by 37.06% to $23.4 million in 2026.
- The last three Research & Development figures came in at $23.4 million (Q1 2026), $17.0 million (Q4 2025), and $23.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - | 24.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.05 Mn |
| Mar 31, 2026 | 23.35 Mn |
| Dec 31, 2025 | 17.04 Mn |
| Sep 30, 2025 | 23.94 Mn |
| Jun 30, 2025 | 13.98 Mn |
| Mar 31, 2025 | 14.50 Mn |
| Dec 31, 2024 | 16.03 Mn |
| Sep 30, 2024 | 16.77 Mn |
| Jun 30, 2024 | 21.10 Mn |
| Mar 31, 2024 | 16.37 Mn |
| Dec 31, 2023 | 22.26 Mn |
| Sep 30, 2023 | 15.87 Mn |
| Jun 30, 2023 | 16.78 Mn |
| Mar 31, 2023 | 18.14 Mn |
| Dec 31, 2022 | 19.10 Mn |
| Sep 30, 2022 | 17.79 Mn |
| Jun 30, 2022 | 16.51 Mn |
| Mar 31, 2022 | 31.68 Mn |
| Dec 31, 2021 | 28.60 Mn |
| Sep 30, 2021 | 28.13 Mn |